Xpovio (selinexor) vs Brukinsa (zanubrutinib)
Xpovio (selinexor) vs Brukinsa (zanubrutinib)
Xpovio (selinexor) is a selective inhibitor of nuclear export, approved for use in multiple myeloma and certain types of diffuse large B-cell lymphoma, working by trapping tumor suppressor proteins within the nucleus to induce cancer cell death. Brukinsa (zanubrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor used to treat mantle cell lymphoma and Waldenström's macroglobulinemia, targeting a key enzyme in the B-cell receptor signaling pathway to prevent cancer cell proliferation and survival. When deciding between Xpovio and Brukinsa, it is crucial to consider the specific type of cancer being treated, as each medication is approved for different indications and works through distinct mechanisms, and to consult with a healthcare professional who can evaluate the individual's medical history and the disease's characteristics to determine the most appropriate treatment option.
Difference between Xpovio and Brukinsa
| Metric | Xpovio (selinexor) | Brukinsa (zanubrutinib) |
|---|---|---|
| Generic name | Selinexor | Zanubrutinib |
| Indications | Multiple myeloma, diffuse large B-cell lymphoma | Mantle cell lymphoma, Waldenström's macroglobulinemia |
| Mechanism of action | Selective inhibitor of nuclear export (SINE) compound that inhibits exportin 1 (XPO1) | Bruton's tyrosine kinase (BTK) inhibitor |
| Brand names | Xpovio | Brukinsa |
| Administrative route | Oral | Oral |
| Side effects | Nausea, vomiting, fatigue, anorexia, weight loss, diarrhea | Neutropenia, thrombocytopenia, anemia, bruising, rash |
| Contraindications | Thrombocytopenia, neutropenia, pregnancy | Bleeding risk, infection risk, cardiac arrhythmias |
| Drug class | Antineoplastic agent | Antineoplastic agent |
| Manufacturer | Karyopharm Therapeutics | BeiGene |
Efficacy
Xpovio (Selinexor) Efficacy in Treating Lymphoma
Xpovio (selinexor) is an oral selective inhibitor of nuclear export (SINE) compound that has shown efficacy in the treatment of certain types of lymphoma. Specifically, selinexor has been approved by the U.S. Food and Drug Administration (FDA) for use in combination with dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma, which is a cancer of plasma cells, a type of white blood cell found in the bone marrow that can be related to lymphoma. Additionally, clinical trials have investigated the use of selinexor in the treatment of diffuse large B-cell lymphoma (DLBCL), which is the most common subtype of non-Hodgkin lymphoma.
In clinical studies, selinexor has demonstrated a capacity to induce responses in patients with heavily pretreated DLBCL, including those who have not responded to other therapies. The efficacy of selinexor in this patient population provides a new therapeutic option for individuals with limited treatment choices. However, the effectiveness of selinexor can vary based on the patient's specific condition and previous treatments, and it is important for patients to discuss the potential benefits and risks with their healthcare provider.
Brukinsa (Zanubrutinib) Efficacy in Treating Lymphoma
Brukinsa (zanubrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor that has shown effectiveness in treating mantle cell lymphoma (MCL), which is a type of non-Hodgkin lymphoma. The FDA has granted accelerated approval to Brukinsa for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy. This approval is based on overall response rate, and continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.
Clinical trials have demonstrated that zanubrutinib can achieve high response rates in patients with MCL, with a significant proportion of patients experiencing partial or complete responses to the treatment. The efficacy of Brukinsa in these studies suggests that it is a potent therapy for MCL, particularly in cases where the disease has relapsed or is refractory to other treatments. As with any medication, the effectiveness of Brukinsa for an individual patient will depend on a variety of factors, and it is essential for patients to have thorough discussions with their healthcare providers about the expected outcomes and potential side effects of the treatment.
Regulatory Agency Approvals
Xpovio
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Brukinsa
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Xpovio or Brukinsa today
If Xpovio or Brukinsa are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us